AU2021361731A1 - Compositions and methods for storage stable ophthalmic drugs - Google Patents

Compositions and methods for storage stable ophthalmic drugs Download PDF

Info

Publication number
AU2021361731A1
AU2021361731A1 AU2021361731A AU2021361731A AU2021361731A1 AU 2021361731 A1 AU2021361731 A1 AU 2021361731A1 AU 2021361731 A AU2021361731 A AU 2021361731A AU 2021361731 A AU2021361731 A AU 2021361731A AU 2021361731 A1 AU2021361731 A1 AU 2021361731A1
Authority
AU
Australia
Prior art keywords
aceclidine
concentration
container
degrees celsius
viscosity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021361731A
Other languages
English (en)
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lenz Therapeutics Inc
Original Assignee
Lenz Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/069,155 external-priority patent/US11273150B2/en
Application filed by Lenz Therapeutics Inc filed Critical Lenz Therapeutics Inc
Publication of AU2021361731A1 publication Critical patent/AU2021361731A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021361731A 2020-10-13 2021-04-28 Compositions and methods for storage stable ophthalmic drugs Pending AU2021361731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/069,155 US11273150B2 (en) 2018-10-10 2020-10-13 Compositions and methods for the treatment of presbyopia
US17/069,155 2020-10-13
PCT/US2021/029536 WO2022081204A1 (en) 2020-10-13 2021-04-28 Compositions and methods for storage stable ophthalmic drugs

Publications (1)

Publication Number Publication Date
AU2021361731A1 true AU2021361731A1 (en) 2023-05-25

Family

ID=81209258

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021361731A Pending AU2021361731A1 (en) 2020-10-13 2021-04-28 Compositions and methods for storage stable ophthalmic drugs

Country Status (8)

Country Link
EP (1) EP4228636A1 (ko)
JP (1) JP2023544918A (ko)
KR (1) KR20230131822A (ko)
CN (1) CN116847841A (ko)
AU (1) AU2021361731A1 (ko)
CA (1) CA3195422A1 (ko)
MX (1) MX2023004298A (ko)
WO (1) WO2022081204A1 (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100393C2 (ru) * 2007-10-16 2012-12-25 Сан Фарма Адвансед Ресьорч Компані Лімітед Новые офтальмологические композиции
US20190038609A1 (en) * 2013-08-28 2019-02-07 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
MX2017016517A (es) * 2015-06-18 2018-05-28 Presbyopia Therapies Llc Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
MA53873A (fr) * 2018-10-10 2022-01-19 Presbyopia Therapies Inc Compositions et procédés pour le traitement de la presbytie

Also Published As

Publication number Publication date
CN116847841A (zh) 2023-10-03
KR20230131822A (ko) 2023-09-14
CA3195422A1 (en) 2022-04-21
WO2022081204A1 (en) 2022-04-21
MX2023004298A (es) 2023-08-09
EP4228636A1 (en) 2023-08-23
JP2023544918A (ja) 2023-10-25

Similar Documents

Publication Publication Date Title
US10836760B2 (en) Compositions and methods for the treatment of presbyopia
US20190038609A1 (en) Compositions and methods for the treatment of presbyopia
US10307408B2 (en) Contact lens compositions and methods for the treatment of presbyopia
WO2017160548A1 (en) Compositions and methods for the treatment of presbyopia
US10052313B2 (en) Compositions and methods for the treatment of presbyopia
US20230414494A1 (en) Compositions and methods for the treatment of presbyopia
US10959990B2 (en) Compositions and methods for the treatment of presbyopia
US20220233434A1 (en) Compositions and methods for the treatment of presbyopia
US10617763B2 (en) Compositions and methods for the treatment of presbyopia
US20190240152A1 (en) Contact lens compositions and methods for the treatment of presbyopia
US20230414587A1 (en) Compositions and methods for storage stable ophthalmic drugs
US20180235946A1 (en) Compositions and methods for the treatment of presbyopia
US11273150B2 (en) Compositions and methods for the treatment of presbyopia
AU2021361731A1 (en) Compositions and methods for storage stable ophthalmic drugs
US20230398064A1 (en) Compositions and methods for the treatment of presbyopia
US11648247B1 (en) Compositions and methods for the treatment of presbyopia
US20230310392A1 (en) Compositions and methods for the treatment of eye conditions
WO2019135927A1 (en) Contact lens compositions and methods for the treatment of presbyopia
WO2023114347A9 (en) Compositions and methods for the treatment of eye conditions
BR122022017130B1 (pt) Composições e métodos para o tratamento da presbiopia